VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 336 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2018. The put-call ratio across all filers is 2.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,003,000 | -45.6% | 86,200 | -62.7% | 0.16% | -54.6% |
| Q1 2018 | $3,682,000 | +59.9% | 231,276 | +108.8% | 0.35% | +13.7% |
| Q4 2017 | $2,302,000 | +99.5% | 110,787 | +37.6% | 0.31% | +46.4% |
| Q3 2017 | $1,154,000 | -60.7% | 80,510 | -52.6% | 0.21% | -51.7% |
| Q2 2017 | $2,939,000 | +796.0% | 169,892 | +472.1% | 0.43% | +312.4% |
| Q1 2017 | $328,000 | -59.5% | 29,697 | -10.0% | 0.10% | +12.9% |
| Q3 2016 | $810,000 | -74.3% | 33,000 | -78.9% | 0.09% | -33.1% |
| Q2 2016 | $3,148,000 | -49.8% | 156,289 | +141.4% | 0.14% | -43.5% |
| Q1 2016 | $6,273,000 | -16.3% | 64,751 | +8685.8% | 0.25% | +5.1% |
| Q4 2015 | $7,492,000 | +414.6% | 737 | -88.8% | 0.23% | +766.7% |
| Q2 2015 | $1,456,000 | +1.8% | 6,553 | -9.0% | 0.03% | -41.3% |
| Q1 2015 | $1,430,000 | +81.5% | 7,200 | +30.9% | 0.05% | +142.1% |
| Q4 2014 | $788,000 | -16.3% | 5,500 | -23.4% | 0.02% | -36.7% |
| Q3 2014 | $942,000 | – | 7,179 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |